Cholesterol Shot vs Add-On Pill Cost Compared

Why This Comparison Matters

Ezetimibe and inclisiran sit at different points on the lipid-lowering treatment ladder, but clinicians increasingly weigh one against the other once a patient on a statin still has not reached an LDL-C goal. The decision is not purely clinical. Out-of-pocket cost, formulary tier, prior authorization burden, and administration logistics shape real-world prescribing as much as trial data does.

Ezetimibe (brand name Zetia) has been available generically since December 2016. Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) that targets hepatic PCSK9 production; it received FDA approval in December 2021 as an adjunct to diet and maximally tolerated statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The two drugs share the goal of lowering LDL-C but differ in mechanism, magnitude of effect, route, frequency, cost, and how much outcomes evidence exists behind each.

No head-to-head randomized trial of ezetimibe versus inclisiran exists. Every efficacy comparison below is a cross-trial comparison, which is a real limitation: trial populations, baseline LDL-C, and background therapy differed between the ezetimibe and inclisiran trials, so the numbers are useful for orientation but should not be read as a controlled comparison.

Mechanism of Action: Two Distinct Pathways

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter on the intestinal brush border, reducing absorption of dietary and biliary cholesterol. This is complementary to statins, which reduce hepatic cholesterol synthesis via HMG-CoA reductase inhibition. Combined with a statin, ezetimibe provides additional LDL-C lowering of roughly 20-25% beyond statin alone.

Inclisiran works differently. It is a synthetic siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocytes, where it silences the messenger RNA that encodes PCSK9. Lower PCSK9 production means more LDL receptors stay on the hepatocyte surface to clear LDL-C from the blood. The ORION-10 and ORION-11 trials showed this mechanism produces LDL-C reductions near 50% when added to maximally tolerated statins, sustained with twice-yearly dosing after loading doses at day 1 and day 90.

Inclisiran is substantially more potent at lowering LDL-C per intervention. Potency alone, however, does not settle where each drug belongs in a treatment plan, and it does not by itself establish cardiovascular benefit.

Efficacy: What the Trials Actually Showed

The strongest outcomes evidence for ezetimibe comes from IMPROVE-IT (N=18,144), published in the New England Journal of Medicine in 2015. Patients within 10 days of an acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. Over a median follow-up of 6 years, the ezetimibe group reached a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL with placebo. The composite primary endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group (HR 0.936, 95% CI 0.89-0.99, P=0.016), a modest but statistically significant relative risk reduction. It took six years and more than 18,000 patients to reach that result, which is worth keeping in mind when interpreting the size of the benefit.

Inclisiran's LDL-lowering effect was established in ORION-10 (N=1,561) and ORION-11 (N=1,617), both published in the New England Journal of Medicine in 2020. At day 510, time-adjusted LDL-C reductions were 51% and 54% relative to placebo, from baseline LDL-C in the range of 100-105 mg/dL.

A key limitation: neither ORION-10 nor ORION-11 was powered to detect a difference in cardiovascular events. The dedicated outcomes trial, ORION-4 (NCT03705234), enrolled roughly 15,000 patients with established ASCVD and was designed to report cardiovascular outcomes on a longer timeline; at the time this article was written, results had not yet been confirmed as published. Anyone citing an ORION-4 result to a patient should verify its current status directly at ClinicalTrials.gov before relying on it, since trial timelines shift and this article's source material does not confirm a completion date.

In the absence of a completed inclisiran outcomes trial, some clinicians reason from the broader statin-era observation that LDL-C lowering by various mechanisms tends to track with proportional reductions in cardiovascular events. That reasoning is an extrapolation from other drug classes, not a result specific to inclisiran, and it should be presented to patients as inference rather than proof.

The 2018 AHA/ACC/multi-society cholesterol guideline positions ezetimibe as the standard first add-on for patients not at LDL-C goal on maximally tolerated statin, with PCSK9-targeting therapies considered for higher-risk patients who remain above goal after statin plus ezetimibe. Guideline language has been updated since 2018 as PCSK9 siRNA therapy has entered practice; clinicians should confirm the current version of the guideline they are applying rather than relying on the 2018 document alone.

Choosing Between Ezetimibe and Inclisiran: A Decision Framework

No single factor decides between these two drugs. The table below lays out the variables that most often change the decision in practice, with the evidence behind each row.

Use this comparison as a foundation for discussing cardiometabolic options with your prescriber, but not as a replacement for that conversation. The table does not reflect individual patient factors like coexisting conditions, concurrent medications, or insurance coverage policies, which require direct verification.

Cost Comparison: List Price, Generic, and Real-World

Costs for both drugs vary by pharmacy, plan, and time, so treat the figures here as directional and confirm current pricing before discussing cost with a patient.

Ezetimibe (generic Zetia): Brand-name Zetia carried a wholesale acquisition cost (WAC) that exceeded $300 per month before generic entry. Since the 2016 generic launch, out-of-pocket costs for ezetimibe 10 mg daily commonly fall in the $10-$30 per month range at retail pharmacies, sometimes lower with a discount card. Most commercial plans and Medicare Part D formularies place generic ezetimibe at Tier 1 or Tier 2, and prior authorization is uncommon.

Inclisiran (Leqvio): The manufacturer's list (WAC) price is roughly $3,250 per injection. The FDA-approved schedule is an initial dose, a second dose at 90 days, then maintenance dosing every 6 months, so year one involves three injections and subsequent years involve two. At list price that works out to roughly $9,750 in year one and $6,500 in later years, though few patients pay list price. The manufacturer offers copay assistance for eligible commercially insured patients, and separate assistance programs exist for uninsured or underinsured patients, but these programs have eligibility rules and do not eliminate cost for everyone. Because inclisiran is administered in a physician's office, it is typically billed under a patient's medical benefit rather than a pharmacy benefit; for Medicare beneficiaries this generally falls under Part B, which carries roughly 20% coinsurance after the deductible unless supplemental coverage applies. CMS publishes current Part B coverage and cost-sharing rules, which should be checked directly rather than assumed, since coinsurance amounts depend on the negotiated payment rate in effect at the time of service.

The gap between the two drugs' cost is large by any reasonable estimate, commonly ten times or more depending on payer negotiation and assistance eligibility, which makes cost the single largest practical differentiator in this comparison.

Insurance Access and Prior Authorization

Generic ezetimibe is on essentially every U.S. formulary without restriction, needs no step therapy, and can be prescribed by any licensed provider and filled at any pharmacy.

Inclisiran typically requires prior authorization from commercial payers and Medicare Administrative Contractors. Common documentation requirements include:

1. A diagnosis of ASCVD or heterozygous familial hypercholesterolemia (HeFH)
2. Current use of maximally tolerated statin therapy (or documented statin intolerance)
3. LDL-C still above a plan-specific threshold despite that therapy
4. A prior trial of ezetimibe in many cases (step therapy)
5. On some plans, a prior trial of or documented intolerance to a PCSK9 monoclonal antibody

Because these requirements are payer-specific and change over time, confirm current criteria with the patient's plan rather than assuming any one list applies universally.

In-office administration adds a logistics layer beyond insurance approval. The prescribing practice must stock the drug, administer the injection, and bill the appropriate benefit; practices without buy-and-bill infrastructure may need to refer patients to an infusion center or specialty pharmacy partner.

Adherence and Convenience

Ezetimibe requires a daily pill, and real-world adherence to daily oral lipid-lowering therapy is often lower than clinicians expect. A 2019 analysis of ezetimibe adherence in a Medicare population found roughly 50-60% of patients had a proportion of days covered (PDC) of 80% or higher at 12 months, similar to the adherence challenges seen with daily statins.

Inclisiran's twice-yearly, in-office dosing removes the day-to-day adherence decision: if the patient attends the appointment, they receive the full dose. In ORION-10 and ORION-11, injection adherence exceeded 97%. For a patient with a documented pattern of missing daily doses, this administration model can produce more consistent LDL-C control over time, provided the patient is able and willing to attend twice-yearly visits.

Safety Profile Comparison

Ezetimibe has been marketed since 2002, so more than two decades of real-world experience back its safety profile. In IMPROVE-IT, rates of myopathy, rhabdomyolysis, gallbladder events, hepatitis, and cancer did not differ significantly between the ezetimibe and placebo groups over 6 years. The most common side effects (upper respiratory infection, diarrhea, arthralgia) occurred at rates similar to placebo.

Inclisiran's safety data come mainly from the 18-month ORION-10 and ORION-11 trials and their extensions. Injection-site reactions occurred in about 5% of inclisiran patients versus 0.7% with placebo, generally mild and rarely leading to discontinuation. No hepatotoxicity, excess myalgia, or neurocognitive safety signal emerged in those trials. Inclisiran has roughly 4 years of post-marketing experience as of 2026, compared with more than 20 years for ezetimibe, so rare or long-latency effects are less thoroughly characterized. The FDA-approved prescribing information is the authoritative source for current warnings and should be checked directly for any patient-specific safety question.

Who Should Get Which Drug?

This is usually a sequencing question rather than an either/or choice. Guideline-based practice positions ezetimibe as the standard first add-on to a statin (2018 AHA/ACC guideline, with more recent PCSK9-related guidance updates that should be checked for current recommendations). Inclisiran is generally considered later, after ezetimibe has been tried and LDL-C remains above goal.

Ezetimibe is a reasonable first step when:

• A patient on maximally tolerated statin needs a further LDL-C reduction in the range shown in IMPROVE-IT
• Cost sensitivity or formulary access is a major concern
• There is no established ASCVD and the patient is in a primary prevention population
• The patient can reliably take a daily oral medication

Inclisiran may be appropriate when:

• LDL-C remains above goal despite statin plus ezetimibe
• The patient has a documented history of poor adherence to daily oral lipid-lowering therapy
• The patient has HeFH and needs substantial additional LDL-C reduction
• The patient cannot tolerate or prefers to avoid frequent self-injection of a PCSK9 monoclonal antibody

A common clinical sequence for a high-risk ASCVD patient: start or optimize a high-intensity statin, add ezetimibe if LDL-C remains above goal, then consider inclisiran or a PCSK9 monoclonal antibody if the target is still not met. This mirrors both current guideline sequencing and typical payer coverage logic, though any individual dosing or treatment decision should be made by the treating clinician based on the full clinical picture.

Inclisiran vs PCSK9 Monoclonal Antibodies: A Brief Note on the Broader Context

Clinicians choosing inclisiran are often also weighing it against the PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent). Unlike inclisiran, both monoclonal antibodies have their own completed cardiovascular outcomes trials: evolocumab in FOURIER and alirocumab in ODYSSEY OUTCOMES. Net prices for the monoclonal antibodies have come down since launch and in some plans approach inclisiran's net cost. The practical advantage of inclisiran over the monoclonal antibodies is dosing frequency: two office-administered injections a year versus 12-26 self-administered injections a year. This article does not attempt a full ezetimibe-versus-evolocumab or ezetimibe-versus-alirocumab comparison; it is included here only for treatment-selection context.

The Bottom Line on Value

Generic ezetimibe offers a modest, trial-proven cardiovascular benefit at low monthly cost with essentially no access barriers. Inclisiran delivers substantially more LDL-C lowering for a much higher price, with prior authorization requirements, in-office administration logistics, and, as of this writing, no completed dedicated cardiovascular outcomes trial of its own.

For most patients who need additional LDL-C lowering beyond a statin, adding ezetimibe first remains the most cost-effective and best-evidenced next step. Inclisiran fits patients with ASCVD or HeFH whose LDL-C stays above guideline thresholds despite statin plus ezetimibe, or whose adherence to daily oral therapy has been documented as unreliable. The ORION-4 outcomes trial, once its results are confirmed published, will clarify whether inclisiran's large LDL-C reduction translates into a proportional reduction in cardiovascular events; until then, treat that link as a reasonable hypothesis rather than an established fact, and verify current guideline recommendations and current drug pricing before advising a specific patient.